ClinicalTrials.gg
RecruitingNCT07187635Updated Nov 3, 2026

Guiding Value of Urinary Tumor DNA Testing in Repeat Transurethral Resection of Non-Muscle-Invasive Bladder Cancer

An interventional study of Second Transurethral Resection of Bladder Tumor (re-TURBT) and utDNA Testing (Urine Tumor DNA Detection) in Bladder Cancer, Liquid Biopsy and Repeat Transurethral Resection of Bladder Tumor, sponsored by Tianjin Medical University Second Hospital. Recruiting at 7 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-03.

Sponsored by Tianjin Medical University Second Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Sep 2025; still recruiting 1 year 1 month later.
Updated Nov 3, 2026Enrollment updatedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
350
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 194 studies in Urinary Bladder Neoplasms with a site in China — 102 open to participants now, 119 under way, 17 of them phase 3. Urinary Bladder Neoplasms · China.

Planned enrollment
27th of 141
350 · median 75
Started
2025
with 28 others
No phase
33 of 194
20 open now
Primary completion
2027-10
later than 68 of 118 live
Registered
151st of 194
by date
Lead sponsor
9 of 194
Tianjin Medical University Second Hospital

Among the 194 studies in Urinary Bladder Neoplasms with a site in China, this one is the 27th largest by planned enrollment of the 141 interventional ones that give a count, is one of 29 that started in 2025, is one of 33 with no phase, reaches primary completion later than 68 of the 118 other live ones, and was the 151st registered.

Urinary Bladder Neoplasms

1,803 studies on the registry are indexed under Urinary Bladder Neoplasms; 446 are open to participants now.

Browse Urinary Bladder Neoplasms studies →

Open to participants now

102 of the 194 studies in Urinary Bladder Neoplasms with a site in China are open now. Recruiting first, the newest first:

96 more — sign in →

All 102 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 336 Urinary Bladder Neoplasms studies recruiting now, 256 (76%) set no upper age limit and 22 (7%) stop at 75 or younger; 22 take children under 18; 21 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 194 studies in Urinary Bladder Neoplasms with a site in China, or all of them as a file.
02

Study summary

Non-muscle-invasive bladder cancer (NMIBC) accounts for approximately 75% of newly diagnosed bladder cancers and is characterized by a high risk of recurrence and progression. Current guidelines recommend that patients with stage T1 NMIBC undergo a second transurethral resection of bladder tumor (re-TURBT) within 2-6 weeks after the initial surgery to remove residual tumor, confirm staging, and obtain additional pathological information. However, the benefits of routine re-TURBT for all high-risk patients remain controversial, as many patients may not have residual disease, while the procedure carries surgical and anesthetic risks, physical and psychological burden, and additional healthcare costs.

Urine tumor DNA (utDNA) refers to DNA fragments shed by tumor cells into urine. It can be detected using molecular assays with high sensitivity and specificity, offering a non-invasive method for bladder cancer diagnosis and surveillance. Previous studies have shown that positive utDNA results after initial TURBT may be associated with residual disease and higher recurrence risk.

This multicenter, randomized controlled trial aims to evaluate whether utDNA testing can accurately identify NMIBC patients who are most likely to benefit from re-TURBT, thereby guiding the decision to perform the procedure. The goal is to optimize patient selection for re-TURBT, reduce unnecessary surgeries, and improve patient quality of life while maintaining oncologic safety.

03

Conditions studied

  • Bladder Cancer
  • Liquid Biopsy
  • Repeat Transurethral Resection of Bladder Tumor

Keywords

  • bladder cancer
  • liquid biopsy
  • second transurethral resection of bladder tumor
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Participants must meet all of the following criteria to be eligible for the study:

  1. Male or female, aged 18 years or older.
  2. confirmed non-muscle-invasive bladder tumor, with no evidence of muscle-invasive bladder cancer or disease.
  3. Histologically confirmed urothelial carcinoma of the bladder or bladder tumor with urothelial carcinoma as the predominant component (>50%).
  4. At least one of the following conditions:

    1. Incomplete initial transurethral resection of bladder tumor (TURBT) or suspected incomplete resection.
    2. Absence of detrusor muscle in the initial TURBT pathological specimen (except for low-grade Ta stage tumors or carcinoma in situ [CIS]).
    3. T1 stage tumor.
  5. Willingness to provide a 50 mL urine sample between 2-6 weeks after the initial TURBT and prior to re-TURBT.
  6. Willingness to provide tumor tissue samples for pathological examination.
  7. Willingness to undergo genetic testing required for the trial.

Exclusion criteria

Exclusion Criteria:

  1. to transurethral resection of bladder tumor (TURBT).
  2. Concurrent of the upper urinary tract (ureter or renal pelvis).
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
350 participants (estimated)

Study arms

  • Active comparator
    Standard re-TURBT

    Participants with NMIBC who have undergone initial TURBT will not receive utDNA testing and will undergo a second transurethral resection of bladder tumor (re-TURBT) within 2-6 weeks after the initial surgery, per guideline-based management.

    Procedure: Second Transurethral Resection of Bladder Tumor (re-TURBT)

  • Experimental
    utDNA-guided management

    Participants with NMIBC who have undergone initial TURBT will receive urine tumor DNA (utDNA) testing. If utDNA positive, they will undergo re-TURBT within 2-6 weeks after the initial surgery. If utDNA negative, re-TURBT will be omitted and patients will continue guideline-based adjuvant therapy/surveillance as per protocol.

    Diagnostic Test: utDNA Testing (Urine Tumor DNA Detection)

Interventions

  • ProcedureSecond Transurethral Resection of Bladder Tumor (re-TURBT)

    Participants with NMIBC who have undergone initial TURBT will not receive utDNA testing and will undergo a second transurethral resection of bladder tumor (re-TURBT) within 2-6 weeks after the initial surgery, in accordance with current clinical guidelines.

  • Diagnostic testutDNA Testing (Urine Tumor DNA Detection)

    Participants with NMIBC who have undergone initial TURBT will receive urine tumor DNA (utDNA) testing. If utDNA is positive, the patient will undergo a second transurethral resection of bladder tumor (re-TURBT) within 2-6 weeks after the initial surgery. If utDNA is negative, re-TURBT will be omitted and patients will proceed to guideline-based adjuvant therapy or surveillance.

06

What researchers measure

Primary outcomes

  1. Recurrence-free survival (RFS)

    Time from randomization to the first documented event of bladder tumor recurrence (any grade), upper tract urothelial recurrence.

    Time frame: Up to 24 months from randomization

Secondary outcomes

  1. Progression-free survival (PFS)

    Time from initial TURBT to disease progression (development of muscle-invasive bladder cancer, distant metastasis).

    Time frame: Up to 24 months from randomization

  2. Pathological outcomes of second transurethral resection (re-TURBT)

    Proportion of patients with residual tumor, upstaging (higher T category at re-TURBT), or concomitant CIS among those undergoing repeat TURBT.

    Time frame: Perioperative (day of repeat TURBT)

  3. Patient-reported outcomes

    Health outcomes directly reported by the patient without interpretation by clinicians or others. These measures capture patients' perceptions of symptoms, functional status, health-related quality of life (HRQoL), and treatment-related burden.

    Time frame: Up to 24 months from randomization.

Other outcomes

  1. Correlation Between utDNA Status and Clinical Outcomes

    Association of urine utDNA results with cystoscopy findings, imaging results, and re-TURBT pathology; evaluation of diagnostic performance (sensitivity, specificity, predictive values, AUC) and relation to recurrence/progression.

    Time frame: Up to 24 months from randomization

07

Study locations

7 of 7 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes

Supporting information: Study protocol, Informed consent form

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2025 (actual). Primary completion is estimated for Oct 2027, 24 months after the start.

Of 237 non-industry interventional studies with no phase under Urinary Bladder Neoplasms, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 69. This study's planned 24 months is below that.

Counting every sponsor, half of 246 studies reached it within 38 months; a quarter within 18 and three quarters within 69.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 11, 2025
First posted
Sep 23, 2025
StartActual
Sep 28, 2025
Primary completionEst.
Oct 1, 2027
CompletionEst.
Nov 1, 2027
Last update
Nov 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Enrollment
196→350
Nov 3, 2026
Show all 1 update
  1. Nov 3, 2026
    Enrollment 196→350

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07187635
Lead sponsor
Tianjin Medical University Second Hospital
Responsible party
Sponsor
First posted
Sep 23, 2025
Start date
Sep 28, 2025
Primary completion
Oct 1, 2027 (estimated)
Completion
Nov 1, 2027 (estimated)
Last update
Nov 3, 2026

Study contacts

Hailong Hu, MD
Contact
huhailong@tmu.edu.cn
+8613662096232

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion